Join
Live feed
·
PRReleasevia Quantisnow
Eli Lilly and Company logo

Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years

ByQuantisnow·Wall Street's wire, on your screen.
LLY· Eli Lilly and Company
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track LLY (Eli Lilly and Company) and more on Quantisnow.